Does niacinamide help rosacea? What the research shows

The short answer: barrier support, not a proven rosacea treatment

Niacinamide may help rosacea-prone skin feel calmer, but we found no large trial showing it clears redness or flares. The most direct evidence is a small study that measured skin barrier function, not rosacea lesions. Mayo Clinic says face products containing niacinamide, azelaic acid, or a dicarboxylic acid may help symptoms, and that they are sold without a prescription (Mayo Clinic on rosacea treatment).

Think of niacinamide as a supporting player. Rosacea skin is often dry and reactive, so a moisturizer that strengthens the barrier is a reasonable thing to try. That is a plausible mechanism, not proof of clinical benefit. For background on what the ingredient does, see our niacinamide explainer.

The one rosacea-specific trial is small, and its numbers are unverified

A 2005 randomized, investigator-blinded study by Draelos and colleagues tested a niacinamide-containing facial moisturizer in 50 people with rosacea (PubMed record for the Draelos study). Participants applied it to the face and one forearm twice daily for four weeks, while the other forearm served as an untreated control.

Outcomes included barrier function, hydration, an investigator rating of rosacea, and self-assessment. We could not retrieve the reported results, effect sizes, or the niacinamide concentration, so we are not quoting any numbers from it. Read the full text before you put weight on its findings.

Secondhand, DermNet reports that at least two studies found niacinamide moisturizers improved barrier function in rosacea and reduced reactions to irritants such as cleansers and cosmetics (DermNet on nicotinamide). We could only verify that through DermNet's summary, not the underlying papers.

Combination products have better trial data, but not for niacinamide alone

A 30-day split-face randomized trial of M89PF, a Vichy product with mineralizing water, probiotic fractions, hyaluronic acid, niacinamide and tocopherol, reported significant improvements in erythema, dryness, tightness and sensitivity in adults with rosacea-associated redness and sensitive skin (randomized trial of a Vichy dermocosmetic). Because niacinamide was one of several ingredients, that result cannot be credited to it.

A different molecule often gets confused with niacinamide. A two-week pilot of 34 patients used a 0.25% gel of 1-methylnicotinamide, a niacinamide metabolite, and reported improvement in 76.4% (26 of 34) (review on vitamins and nutrients in rosacea). That is a small pilot of a different compound, not evidence for niacinamide.

Oral niacinamide and the wider claims need more caution

Oral niacinamide is sold over the counter in 500 mg tablets, but we did not find oral dosing studies for rosacea. High-dose regimens used for other conditions do not transfer to rosacea, so don't self-dose based on them.

A 2025 narrative review lists rosacea among niacinamide's uses and says clinical studies support its effects, with good tolerability over long-term use. It reports no quantitative rosacea outcomes in what we could access, so we weigh it lightly (review of niacinamide as a multifunctional agent).

Two commonly cited studies are not rosacea evidence. A 4% niacinamide gel was compared with 1% clindamycin in acne, and a 5% split-face trial in aging skin improved redness and blotchiness (DermNet on nicotinamide). A 2024 serum trial enrolled healthy people without rosacea, so we excluded it (pilot study of a niacinamide serum).

How to try it without overpromising

If you want to test a niacinamide moisturizer, treat it as a barrier product, not a cure. Choose a fragrance-free formula, patch test on a small area first, and give it at least four weeks, the length of the main trial. Stop if it stings or burns.

Keep any prescription plan you have, and see a dermatologist if redness persists or your skin gets worse. We did not find a professional guideline that recommends niacinamide for rosacea, and we have not yet checked the full AAD and NRS guidance on this point.